scholarly journals A Rapid Antigen Detection Test to Diagnose SARS-CoV-2 Infection Using Exhaled Breath Condensate by A Modified Inflammacheck® Device

Sensors ◽  
2021 ◽  
Vol 21 (17) ◽  
pp. 5710 ◽  
Author(s):  
Mauro Maniscalco ◽  
Pasquale Ambrosino ◽  
Anna Ciullo ◽  
Salvatore Fuschillo ◽  
Valerio Valente ◽  
...  
Keyword(s):  
Diagnostic Accuracy ◽  
Exhaled Breath Condensate ◽  
False Negative ◽  
Antigen Detection ◽  
Routine Practice ◽  
Study Cohort ◽  
Exhaled Breath ◽  
Rt Pcr ◽  
Rapid Antigen Detection Test ◽  
Breath Condensate

Background: The standard test that identifies the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is based on reverse transcriptase-polymerase chain reaction (RT-PCR) from nasopharyngeal (NP) swab specimens. We compared the accuracy of a rapid antigen detection test using exhaled breath condensate by a modified Inflammacheck® device with the standard RT-PCR to diagnose SARS-CoV-2 infection. Methods: We performed a manufacturer-independent, cross-sectional, diagnostic accuracy study involving two Italian hospitals. Sensitivity, specificity, positive (PLR) and negative likelihood ratio (NLR), positive (PPV) and negative predictive value (NPV) and diagnostic accuracy with 95% confidence intervals (95% CI) of Inflammacheck® were calculated using the RT-PCR results as the standard. Further RT-PCR tests were conducted on NP specimens from test positive subjects to obtain the Ct (cycle threshold) values as indicative evidence of the viral load. Results: A total of 105 individuals (41 females, 39.0%; 64 males, 61.0%; mean age: 58.4 years) were included in the final analysis, with the RT-PCR being positive in 13 (12.4%) and negative in 92 (87.6%). The agreement between the two methods was 98.1%, with a Cohen’s κ score of 0.91 (95% CI: 0.79–1.00). The overall sensitivity and specificity of the Inflammacheck® were 92.3% (95% CI: 64.0%–99.8%) and 98.9% (95% CI: 94.1%–100%), respectively, with a PLR of 84.9 (95% CI: 12.0–600.3) and a NLR of 0.08 (95% CI: 0.01–0.51). Considering a 12.4% disease prevalence in the study cohort, the PPV was 92.3% (95% CI: 62.9%–98.8%) and the NPV was 98.9% (95% CI: 93.3%–99.8%), with an overall accuracy of 98.1% (95% CI: 93.3%–99.8%). The Fagan’s nomogram substantially confirmed the clinical applicability of the test in a realistic scenario with a pre-test probability set at 4%. Ct values obtained for the positive test subjects by means of the RT-PCR were normally distributed between 26 and 38 cycles, corresponding to viral loads from light (38 cycles) to high (26 cycles). The single false negative record had a Ct value of 33, which was close to the mean of the cohort (32.5 cycles). Conclusions: The modified Inflammacheck® device may be a rapid, non-demanding and cost-effective method for SARS-CoV-2 detection. This device may be used for routine practice in different healthcare settings (community, hospital, rehabilitation).

scholarly journals Exhaled breath is a significant source of SARS-CoV-2 emission

2020 ◽  
Author(s):  
Jianxin Ma ◽  
Xiao Qi ◽  
Haoxuan Chen ◽  
Xinyue Li ◽  
Zheng Zhang ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Rt Pcr ◽  
Chain Reaction ◽  
Air Samples ◽  
Positive Rate ◽  
Polymerase Chain ◽  
Floor Surfaces ◽  
Breath Condensate

AbstractDespite notable efforts in airborne SARS-CoV-2 detection, no clear evidence has emerged to show how SARS-CoV-2 is emitted into the environments. Here, 35 COVID-19 subjects were recruited; exhaled breath condensate (EBC), air samples and surface swabs were collected and analyzed for SARS-CoV-2 using reverse transcription-polymerase chain reaction (RT-PCR). EBC samples had the highest positive rate (16.7%, n = 30), followed by surface swabs(5.4%, n = 242), and air samples (3.8%, n = 26). COVID-19 patients were shown to exhale SARSCoV-2 into the air at an estimated rate of 103-105 RNA copies/min; while toilet and floor surfaces represented two important SARS-CoV-2 reservoirs. Our results imply that airborne transmission of SARS-CoV-2 plays a major role in COVID-19 spread, especially during the early stages of the disease.One Sentence SummaryCOVID-19 patient exhales millions of SARS-CoV-2 particles per hour

RT-PCR diagnosis of COVID-19 from exhaled breath condensate: a clinical study

2021 ◽  
Author(s):  
Makoto Sawano ◽  
Kyousuke Takeshita ◽  
Hideaki Ohno ◽  
HIdeaki Oka
Keyword(s):  
Clinical Study ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Rt Pcr ◽  
Pcr Diagnosis ◽  
Breath Condensate

The novel detection of EGFR-T790M mutations in exhaled breath condensate.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 9032-9032
Author(s):  
Robert Smyth ◽  
Sinead Toomey ◽  
Alexander Sartori ◽  
Emer O. Hanrahan ◽  
Sinead Cuffe ◽  
...  
Keyword(s):  
Somatic Mutation ◽  
Exhaled Breath Condensate ◽  
False Negative ◽  
Detection Methods ◽  
Future Research ◽  
Common Mechanism ◽  
Exhaled Breath ◽  
Liquid Biopsies ◽  
Breath Condensate ◽  
Egfr T790m

9032 Background: The EGFR-T790M somatic mutation is the most common mechanism of resistance to Tyrosine Kinase Inhibitors (TKI) in NSCLC. However patients with advanced disease are not always amenable to repeat biopsy for further molecular analysis. Developing non-invasive methods to detect T790M in cell-free DNA (cfDNA), in the absence of tissue is being actively investigated. Furthermore these 'liquid biopsies' may also overcome the problem of tumour genomic heterogeneity. Unfortunately the sensitivity of plasma for T790M detection has been disappointing with a significant chance of a false negative result. Exhaled breath condensate (EBC) is an easily collected sample and is known to harbour cfDNA, including lung cancer mutations. We explored the potential of EBC as a novel method of T790M detection. Methods: We recruited 26 patients who were either 1) known T790M positive pre/during Osimertinib therapy or 2) other mEGFR positive patients on 1st/2nd generation TKI. We collected matched plasma and EBC samples in the majority of cases. EBC samples were collected using the RTube device. Plasma was collected using standard EDTA tubes and extracted within 90 minutes. Using UltraSEEK chemistry, a targeted PCR for ultra-sensitive somatic mutation profiling on the MassARRAY system (Agena Bioscience), we compared the performance of EBC to plasma for the detection of T790M. Results: See Table. Conclusions: In this pilot study we describe the first ever report of the successful and consistent detection of T790M in the EBC of patients with EGFR mutated NSCLC, using a commercially available targeted assay. Our results suggest EBC is responsive to recognised dynamic molecular changes that occur on TKI treatment. We believe this makes EBC analysis an attractive avenue for future research, to optimise the detection of T790M mutations in liquid biopsies. [Table: see text]

scholarly journals Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)

Thorax ◽  
2020 ◽  
Vol 76 (1) ◽  
pp. 86-88
Author(s):  
Daniel J Ryan ◽  
Sinead Toomey ◽  
Stephen F Madden ◽  
Michelle Casey ◽  
Oscar S Breathnach ◽  
...  
Keyword(s):  
Reverse Transcriptase ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Rt Pcr ◽  
False Negatives ◽  
Reverse Transcriptase Pcr ◽  
S Gene ◽  
Gene Assay ◽  
Respiratory Droplets ◽  
Breath Condensate

False negatives from nasopharyngeal swabs (NPS) using reverse transcriptase PCR (RT-PCR) in SARS-CoV-2 are high. Exhaled breath condensate (EBC) contains lower respiratory droplets that may improve detection. We performed EBC RT-PCR for SARS-CoV-2 genes (E, S, N, ORF1ab) on NPS-positive (n=16) and NPS-negative/clinically positive COVID-19 patients (n=15) using two commercial assays. EBC detected SARS-CoV-2 in 93.5% (29/31) using the four genes. Pre-SARS-CoV-2 era controls (n=14) were negative. EBC was positive in NPS negative/clinically positive patients in 66.6% (10/15) using the identical E and S (E/S) gene assay used for NPS, 73.3% (11/15) using the N/ORF1ab assay and 14/15 (93.3%) combined.

Preliminary Analysis of the Proteome of Exhaled Breath Condensate in Bottlenose Dolphins (Tursiops truncatus)

2018 ◽  
Vol 44 (3) ◽  
pp. 256-266 ◽  
Author(s):  
Don R. Bergfelt ◽  
John Lippolis ◽  
Michel Vandenplas ◽  
Sydney Davis ◽  
Blake A. Miller ◽  
...  
Keyword(s):  
Preliminary Analysis ◽  
Tursiops Truncatus ◽  
Exhaled Breath Condensate ◽  
Bottlenose Dolphins ◽  
Exhaled Breath ◽  
Breath Condensate

Simultaneous and Sensitive Determination of Amphetamine, Codeine and Morphine in Exhaled Breath Condensate, Using Capillary Electrophoresis Coupled with On-line and Off-line Enhancing Methods

2020 ◽  
Vol 16 (7) ◽  
pp. 872-879
Author(s):  
Samin Hamidi
Keyword(s):  
Drugs Of Abuse ◽  
Exhaled Breath Condensate ◽  
Direct Injection ◽  
Forensic Toxicology ◽  
Analytical Signal ◽  
Exhaled Breath ◽  
Concentration Method ◽  
Validation Parameters ◽  
Breath Condensate

Background: Abuse of drugs is associated with several medical, forensic, toxicology and social challenges. “Drugs of abuse” testing is therefore an important issue. Objective: We propose a simple CE-based method for the quantification of amphetamine, codeine and morphine after direct injection of Exhaled Breath Condensate (EBC) by the aid of simple stacking mode and an off-line pre-concentration method. Methods: Using graphene oxide adsorbents, amphetamine, codeine and morphine were extracted from EBC in order to eliminate the proteins and other interferences. In addition to off-line method, an online stacking mode was applied to improve the analytical signal obtained from the instrument. Results: The validation parameters were experimented on the developed method based on the FDA guideline over concentration ranges of 12.5-100, 30-500 and 10-1250 ng/mL associated with amphetamine, codeine and morphine, respectively. Small volumes (around 100 μL) of EBC were collected using a lab-made setup and successfully analyzed using the proposed method where precisions and accuracies (within day and between days) were in accordance with the guideline (recommended less than 15 % for biological samples). The recovery tests were used to evaluate the matrix effect and data (94 to 105 %) showed that the proposed method can be applied in different EBC matrix samplings of subjects. Conclusion: The proposed method is superior for simultaneous determination of amphetamine, codeine and morphine over chromatographic analyses because it is fast and consumes fewer chemicals, with no derivatization step.

Microextraction and Chromatographic Analysis of Budesonide Epimers in Exhaled Breath Condensate

2020 ◽  
Vol 16 (8) ◽  
pp. 1032-1040
Author(s):  
Laleh Samini ◽  
Maryam Khoubnasabjafari ◽  
Mohamad M. Alimorad ◽  
Vahid Jouyban-Gharamaleki ◽  
Hak-Kim Chan ◽  
...  
Keyword(s):  
Biological Fluids ◽  
Exhaled Breath Condensate ◽  
Low Cost ◽  
Exhaled Breath ◽  
Chromatography Method ◽  
Extraction Solvent ◽  
Drug Concentrations ◽  
Dispersive Liquid Liquid Microextraction ◽  
Breath Condensate

Background: Analysis of drug concentrations in biological fluids is required in clinical sciences for various purposes. Among other biological samples, exhaled breath condensate (EBC) is a potential sample for follow up of drug concentrations. Methods: A dispersive liquid-liquid microextraction (DLLME) procedure followed by a validated liquid chromatography method was employed for the determination of budesonide (BDS) in EBC samples collected using a homemade setup. EBC is a non-invasive biological sample with possible applications for monitoring drug concentrations. The proposed analytical method is validated according to the FDA guidelines using EBC-spiked samples. Its applicability is tested on EBC samples collected from healthy volunteers receiving a single puff of BDS. Results: The best DLLME conditions involved the use of methanol (1 mL) as a disperser solvent, chloroform (200 μL) as an extraction solvent, and centrifugation rate of 3500 rpm for 5 minutes. The method was validated over a concentration range of 21-210 μg·L-1 in EBC. Inter- and intra-day precisions were less than 10% where the acceptable levels are less than 20%. The validated method was successfully applied for the determination of BDS in EBC samples. Conclusion: The findings of this study indicate that the developed method can be used for the extraction and quantification of BDS in EBC samples using a low cost method.

Determination of Verapamil in Exhaled Breath Condensate by Using Microextraction and Liquid Chromatography

2019 ◽  
Vol 15 (5) ◽  
pp. 535-541 ◽  
Author(s):  
Fariba Pourkarim ◽  
Ali Shayanfar ◽  
Maryam Khoubnasabjafari ◽  
Fariborz Akbarzadeh ◽  
Sanaz Sajedi-Amin ◽  
...  
Keyword(s):  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
High Performance ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Good Precision ◽  
Dispersive Liquid Liquid Microextraction ◽  
Breath Condensate ◽  
Liquid Microextraction

Background:Developing a simple analysis method for quantification of drug concentration is one of the essential issues in pharmacokinetic and therapeutic drug monitoring studies.Objective:A fast and reliable dispersive liquid-liquid microextraction procedure was employed for preconcentration of verapamil in exhaled breath condensate (EBC) samples and this was followed by the determination with high-performance liquid chromatography-ultraviolet detection.Methods:A reverse-phase high-performance liquid chromatography (RP-HPLC) combined with a dispersive liquid-liquid microextraction method (DLLME) was applied for quantification of verapamil in the EBC samples. The developed method was validated according to FDA guidelines.Results:Under the optimum conditions, the method provided a linear range between 0.07 and 0.8 µg.mL-1 with a coefficient of determination of 0.998. The intra- and inter-day relative standard deviation and relative error values of the method were below 15%, which indicated good precision and accuracy. The proposed method was successfully applied for the analysis of verapamil in two real samples with concentrations of 0.07 and 0.09 µg.mL-1.Conclusion:The established HPLC-UV-DLLME method could be applied for the analysis of verapamil in human EBC samples.

scholarly journals Measuring acute pulmonary responses to occupational wildland fire smoke exposure using exhaled breath condensate

2019 ◽  
Vol 75 (2) ◽  
pp. 65-69 ◽  
Author(s):  
Chieh-Ming Wu ◽  
Anna Adetona ◽  
Chi (Chuck) Song ◽  
Luke Naeher ◽  
Olorunfemi Adetona
Keyword(s):  
Wildland Fire ◽  
Exhaled Breath Condensate ◽  
Smoke Exposure ◽  
Exhaled Breath ◽  
Fire Smoke ◽  
Breath Condensate
Sign in / Sign up

Export Citation Format

Share Document